background image

Press Releases

  Date Headline Download
07/12/2017 Korea Approves the World’s First Cell and Gene Therapy for Knee Osteoarthritis
11/01/2016 TissueGene Licensee, Kolon Life Science, Partners with Mitsubishi Tanabe Pharma to Develop and Commercialize Invossa
05/28/2015 TissueGene Announces Presentation and Webcast at the Jefferies 2015 Healthcare Conference with Webcast Link
05/15/2015 TissueGene, Inc. Announces Special Protocol Assessment (SPA) Agreement with the Food and Drug Administration (FDA) for its Phase 3 Clinical Trial of Invossa™ for Patients Suffering from Osteoarthritis of the Knee
05/11/2015 TissueGene, Inc. Presents Phase 2 Data for Its Novel Cell Therapy for the Treatment of Osteoarthritis of the Knee
04/21/2015 TissueGene, Inc. Hires Robert Newman as Chief Operating Officer
12/01/2014 TissueGene, Inc. to Participate in the Buzz of BIO at the 2015 BIO CEO & Investor Conference
11/17/2014 TissueGene Receives Recommendations from FDA on Pathway to Phase 3 Trial of TG-C for Treatment of Osteoarthritis of the Knee
11/14/2012 TissueGene Completes Enrollment in U.S. Phase II Study of TG-C in Patients with Knee Osteoarthritis
05/19/2011 TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee
02/08/2010 PharmaVigilant Supports TissueGene's Phase II Trial with Groundbreaking Imaging Capabilities
03/03/2009 TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
10/03/2007 TissueGene Signs Contract to Locate on Johns Hopkins University – Montgomery County Campus
07/24/2006 TissueGene Initiates Phase I Clinical Trial with TG-C
05/18/2005 TissueGene, Inc. to Present at Windhover Information's ‘The Start-Up Forum 2005
04/19/2005 RheoGene Inc. and TissueGene Inc. Sign Collaborative Agreement for Bone Regeneration and Repair